MX2017008915A - Profarmacos de peptido natriuretico tipo c (cnp). - Google Patents

Profarmacos de peptido natriuretico tipo c (cnp).

Info

Publication number
MX2017008915A
MX2017008915A MX2017008915A MX2017008915A MX2017008915A MX 2017008915 A MX2017008915 A MX 2017008915A MX 2017008915 A MX2017008915 A MX 2017008915A MX 2017008915 A MX2017008915 A MX 2017008915A MX 2017008915 A MX2017008915 A MX 2017008915A
Authority
MX
Mexico
Prior art keywords
cnp
prodrugs
cnp prodrugs
conjugates
poly
Prior art date
Application number
MX2017008915A
Other languages
English (en)
Inventor
Hersel Ulrich
Sprogøe Kennett
Cleemann Felix
Kaluza Nora
Rau Harald
Wegge Thomas
Faltinger Frank
Bernhard Ana
Woods Tom
Buba Annette
Original Assignee
Ascendis Pharma Growth Disorders As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Growth Disorders As filed Critical Ascendis Pharma Growth Disorders As
Publication of MX2017008915A publication Critical patent/MX2017008915A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a los profármacos del péptido natriurético tipo C (CNP), las composiciones farmacéuticas que comprenden tales profármacos de CNP y su uso. En una modalidad, los profármacos de CNP son conjugados de los péptidos de CNP al poli(etilenglicol) a través de un ligador reversible.
MX2017008915A 2015-01-09 2016-01-08 Profarmacos de peptido natriuretico tipo c (cnp). MX2017008915A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15150584 2015-01-09
EP15160457 2015-03-24
PCT/EP2016/050298 WO2016110577A1 (en) 2015-01-09 2016-01-08 Cnp prodrugs

Publications (1)

Publication Number Publication Date
MX2017008915A true MX2017008915A (es) 2018-04-26

Family

ID=55077514

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008915A MX2017008915A (es) 2015-01-09 2016-01-08 Profarmacos de peptido natriuretico tipo c (cnp).
MX2022005466A MX2022005466A (es) 2015-01-09 2017-07-05 Profarmacos de peptido natriuretico tipo c (cnp).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005466A MX2022005466A (es) 2015-01-09 2017-07-05 Profarmacos de peptido natriuretico tipo c (cnp).

Country Status (13)

Country Link
US (4) US20170368189A1 (es)
EP (1) EP3242689A1 (es)
JP (4) JP2018502868A (es)
KR (1) KR102599552B1 (es)
CN (1) CN107405409B (es)
AU (3) AU2016205968A1 (es)
BR (1) BR112017014560A2 (es)
CA (1) CA2972318A1 (es)
IL (2) IL278970B2 (es)
MX (2) MX2017008915A (es)
RU (1) RU2728656C2 (es)
SG (2) SG11201705521YA (es)
WO (1) WO2016110577A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
CA3007976C (en) * 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CN114306629B (zh) 2016-01-08 2023-11-10 阿森迪斯药物生长障碍股份有限公司 具有增加的nep稳定性的控制释放cnp激动剂
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
DK3400019T3 (da) * 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP-prodrugs med bærerbinding ved ringenheden
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
SI3518961T1 (sl) 2016-09-29 2023-07-31 Ascendis Pharma Bone Diseases A/S Spojine PTH z nizkimi razmerji med najvišjo in najnižjo vrednostjo
KR20240013849A (ko) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
PL3518930T3 (pl) 2016-09-29 2023-09-11 Ascendis Pharma Growth Disorders A/S Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CA3129352A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
EP4251150A1 (en) * 2020-11-25 2023-10-04 Prolynx LLC Extended release hydrogel conjugates of c-natriuretic peptides
WO2023117855A1 (en) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024104922A1 (en) * 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3799465B2 (ja) * 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
TWI367213B (en) * 2007-11-21 2012-07-01 Biomarin Pharm Inc Variants of c-type natriuretic peptide
US8906847B2 (en) * 2008-02-01 2014-12-09 Ascendis Pharma A/S Prodrug comprising a drug linker conjugate
WO2010033217A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of cd-np peptides
AR078044A1 (es) * 2009-05-20 2011-10-12 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2011075471A2 (en) * 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US8754190B2 (en) * 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers

Also Published As

Publication number Publication date
JP2018502868A (ja) 2018-02-01
BR112017014560A2 (pt) 2018-01-02
RU2017128291A3 (es) 2019-06-20
JP2022095919A (ja) 2022-06-28
CN107405409A (zh) 2017-11-28
RU2017128291A (ru) 2019-02-11
SG11201705521YA (en) 2017-08-30
IL278970B1 (en) 2023-11-01
US20170368189A1 (en) 2017-12-28
MX2022005466A (es) 2022-05-26
IL253153A0 (en) 2017-09-28
AU2023204227A1 (en) 2023-08-24
IL278970A (en) 2021-01-31
CN107405409B (zh) 2022-03-22
US20230116746A1 (en) 2023-04-13
US20210069339A1 (en) 2021-03-11
IL278970B2 (en) 2024-03-01
CA2972318A1 (en) 2016-07-14
AU2016205968A1 (en) 2017-07-13
SG10202011002WA (en) 2020-12-30
RU2728656C2 (ru) 2020-07-31
AU2021203717A1 (en) 2021-07-08
KR20170105550A (ko) 2017-09-19
AU2016205968A8 (en) 2017-07-20
KR102599552B1 (ko) 2023-11-06
WO2016110577A1 (en) 2016-07-14
JP2021008515A (ja) 2021-01-28
JP2024016208A (ja) 2024-02-06
EP3242689A1 (en) 2017-11-15
US20190255183A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX2022005466A (es) Profarmacos de peptido natriuretico tipo c (cnp).
AU2019201173B2 (en) Novel polypeptides
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
PH12017501863A1 (en) Bioconjugates and uses thereof
MX2016007063A (es) Peptidos terapeuticos.
IL265796A (en) Preparations comprising short peptides derived from pedf and their uses
IL264845B1 (en) Peptides targeting malignant tumors, conjugates and preparations containing them and their uses
MX2018001825A (es) Variantes y conjugados de albumina.
MX2019007152A (es) Peptido novedoso.
DK3548058T3 (da) Sammensætninger omfattende peptid wkdeagkplvk
ZA202004658B (en) Pharmaceutical composition comprising an apl type peptide
IL272931A (en) Peptide conjugates, conjugation process and their uses
IL261112A (en) Conjugations of amino acid and peptide and conjugation process
IL280678A (en) Cell-penetrating peptides
IL252902A0 (en) Amino acid and peptide conjugates and their uses
MX2016011938A (es) Composicion farmaceutica liquida.
IL256925A (en) Targeted structures of psa peptide/mhc complexes and their uses
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
MX2015013263A (es) Conjugados de hemoglobina oxido de polialquileno valerato.
EP3585412A4 (en) STABLE PEPTIDIC COMPOSITIONS
MY183068A (en) Pharmaceutical formulation comprising antibody
IL273725A (en) Peptides from Apanniadam10, preparations containing them and their uses
SE542188C2 (en) Supports for membrane enhanced peptide synthesis
GB201900443D0 (en) Cell-penetrating peptides
GB201713700D0 (en) Peptide conjugates